Skip to main
LFCR
LFCR logo

LFCR Stock Forecast & Price Target

LFCR Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Lifecore Biomedical Inc. is expected to experience significant financial growth, with projected EBITDA increasing from $24.4 million in FY26 (16.8% margin) to $27.3 million in FY27 (19.1% margin), demonstrating an improvement in operational efficiency. Additionally, the company has achieved positive free cash flow (FCF) in the most recent quarter, with projections forecasting an increase from $5.1 million in FY26 to $6.0 million in FY27. This combination of expanding margins and positive cash flow underscores a favorable outlook for Lifecore Biomedical's financial performance.

Bears say

Lifecore Biomedical Inc. exhibits a concerning financial outlook, primarily due to its high leverage ratio and the expectation of minimal revenue growth until calendar year 2027. Although a market growth figure of 10% for fill/finish services is considered reasonable, the actual growth is anticipated to be lower, particularly with the inclusion of small molecule injectables. These factors contribute to a justification for Lifecore's valuation discount compared to its peers in the contract development and manufacturing sector.

LFCR has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lifecore Biomedical Inc (LFCR) Forecast

Analysts have given LFCR a Hold based on their latest research and market trends.

According to 1 analysts, LFCR has a Hold consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lifecore Biomedical Inc (LFCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.